Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jan;27(1):52-54.
doi: 10.1136/ejhpharm-2018-001752. Epub 2018 Dec 1.

Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome

Affiliations
Case Reports

Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome

Maria de Castro Julve et al. Eur J Hosp Pharm. 2020 Jan.

Abstract

Thiscase report concerns a 34-year-old male with a hip prosthesis infection, under treatment with antidepressant and antihypertensive drugs, who presented with an increase in blood pressure after four days of treatment with oral tedizolid. Tedizolid was discontinued, and the dose of antihypertensive was increased. The patient progressively achieved the normalisation of blood pressure values, which allowed a reduction in the antihypertensive agent dose to its usual regimen. No cases of hypertension or serotonin toxicity are described in the initial tedizolid studies, where patients treated with other serotonergic drugs were excluded. However, this does not mean that these effects may not occur in clinical practice, especially in patients under concomitant treatment with this type of medication, because of the greater risk of drug interactions. The causality of this suspected drug reaction was analysed and it was considered as possible. The case has been reported to the pharmacovigilance system.

Keywords: adverse effects; hypertensive crisis; pharmacological interactions; serotonin syndrome; tedizolid.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Evolution of patient’s blood pressure.

References

    1. Zhanel GG, Love R, Adam H, et al. . Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs 2015;75:253–70. 10.1007/s40265-015-0352-7 - DOI - PubMed
    1. Ferrández O, Urbina O, Grau S. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Drug Des Devel Ther 2017;11:65–82. 10.2147/DDDT.S84667 - DOI - PMC - PubMed
    1. Roger C, Roberts JA, Muller L. Clinical pharmacokinetics and pharmacodynamics of oxazolidinones. Clin Pharmacokinet 2018;57:559–75. 10.1007/s40262-017-0601-x - DOI - PubMed
    1. EMA (European Medicines Agency). Summary of product characteristics: Sivextro (tedizolid) [Internet]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info... (accessed 13 Apr 2018).
    1. AEMPS (Spanish Agency of Medicines and Medical Devices). Summary of product characteristics. Zyvoxid (linezolid) [Internet]. https://cima.aemps.es/cima/dochtml/ft/64109/FT_64109.html (accessed 13 Apr 2018).

Publication types

MeSH terms